Plasminogen activator/plasmin system in arthritis and inflammation: Friend or foe?

Arthritis and Rheumatism

Volumn 58, Issue 3, 2008, Pages 645-648

  Hamilton, John A ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRIN; INTERLEUKIN 1; PLASMIN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTHRITIS; BACTERIAL ARTHRITIS; BLEEDING; DISEASE SEVERITY; EDITORIAL; HUMAN; INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; PHENOTYPE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS;

ANIMALS; ARTHRITIS; ARTHRITIS, INFECTIOUS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; PLASMIN; PLASMINOGEN ACTIVATORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 40549099322     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23269     Document Type: Editorial

References (27)

1. Busso N, Hamilton JA. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum 2002;46:2268-79.
2. Hamilton JA, Slywka J. Stimulation of human synovial fibroblast plasminogen activator production by mononuclear cell supernatants. J Immunol 1981;126:851-5.
3. Hamilton JA, Hart PH, Leizer T, Vitti GF, Campbell IK. Regulation of plasminogen activator activity in arthritic joints. J Rheumatol Suppl 1991;27:106-9.
4. Bugge TH, Flick MJ, Daugherty CC, Degen JL. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995;9:794-807.
5. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, et al. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation 1995;92:2585-93.
6. Carmeliet P, Moons L, Ploplis V, Plow E, Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest 1997;99:200-8.
7. Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest 1998;102:41-50.
8. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 2005;166:783-92.
9. Cook AD, Braine EL, Campbell IK, Hamilton JA. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol 2002;160:917-26.
10. Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol 2001;167:1047-52.
11. Nielen MM, van der Horst AR, van Schaardenburg D, van der Horst-Bruinsma IE, van de Stadt RJ, Aarden L, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005;64:1199-204.
12. Rodriguez-Lopez J, Perez-Pampin E, Gomez-Reino JJ, Gonzalez A. Regulatory polymorphisms in extracellular matrix protease genes and susceptibility to rheumatoid arthritis: a case-control study. Arthritis Res Ther 2006;8:R1.
13. Busso N, Peclat V, So A, Sappino AP. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997;56:550-7.
14. Lund LR, Green KA, Stoop AA, Ploug M, Almholt K, Lilla J, et al. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J 2006;25:2686-97.
15. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, et al. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997;185:963-8.
16. Guo Y, Li J, Hagstrom E, Ny T. Protective effects of plasmin(ogen) in Staphylococcus aureus-induced arthritis. Arthritis Rheum 2008;58:764-72.
17. Liu ZQ, Deng GM, Foster S, Tarkowski A. Staphylococcal peptidoglycans induce arthritis. Arthritis Res 2001;3:375-80.
18. Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 1998;4:279-84.
19. Sun H, Ringdahl U, Homeister JW, Fay WP, Engleberg NC, Yang AY, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004;305:1283-6.
20. Lathem WW, Price PA, Miller VL, Goldman WE. A plasminogen-activating protease specifically controls the development of primary pneumonic plague. Science 2007;315:509-13.
21. Judex MO, Mueller BM. Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more. Am J Pathol 2005;166:645-7.
22. Hart PH, Burgess DR, Vitti GF, Hamilton JA. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood 1989;74:1222-5.
23. Hart PH, Vitti GF, Burgess DR, Singleton DK, Hamilton JA. Human monocytes can produce tissue-type plasminogen activator. J Exp Med 1989;169:1509-14.
24. Pelletier JP, Mineau F, Fernandes J, Kiansa K, Ranger P, Martel-Pelletier J. Two NSAIDs, nimesulide and naproxen, can reduce the synthesis of urokinase and IL-6 while increasing PAI-1, in human OA synovial fibroblasts. Clin Exp Rheumatol 1997;15:393-8.
25. Almholt K, Lund LR, Rygaard J, Nielsen BS, Dano K, Romer J, et al. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice. Int J Cancer 2005;113:525-32.
26. Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G, Dichek DA. Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. J Biol Chem 2006;281:15345-51.
27. Shushakova N, Eden G, Dangers M, Zwirner J, Menne J, Gueler F, et al. The urokinase/urokinase receptor system mediates the IgG immune complex-induced inflammation in lung. J Immunol 2005;175:4060-8.